Purpose: The purpose of this study is to evaluate if the differential exchange rates with bulk water between amine and amide protons can be exploited using chemical exchange saturation transfer magnetic resonance (CEST-MR) to monitor the release of glutamate induced by carboxypeptidase G2 (CPG2), an enzyme utilized in cancer gene therapy. Procedures: Z spectra of solutions of the CPG2 substrate, 3,5-difluorobenzoyl-L-glutamate (amide), and glutamate (amine) were acquired at 11.7 T, 37°C, across different pH (5-8). The ability of CEST-MR to monitor CPG2-mediated release of glutamate was assessed in extracts of CPG2-expressing cancer cells and purified solution of CPG2. Results: The addition of CPG2 to a solution containing 3,5-difluorobenzoyl-L-glutamate led to a marked and progressively increasing CEST effect (+3 ppm), concomitant with the timedependent release of glutamate induced by CPG2. Conclusion: CEST-MR allows the detection of CPG2 activity in vitro and supports the translation of CEST-MRI to assess CPG2-based gene therapy in vivo.
Introduction
C hemical exchange saturation transfer magnetic resonance imaging (CEST-MRI) exploits the direct chemical exchange of metabolite protons with the bulk tissue water, enabling the detection of specific tissue metabolites at concentrations that are otherwise below the detection limit of conventional 1 H MRI [1] . Recently, CEST MRI has been successfully utilized to acquire high temporal and spatial resolution images of glutamate (Glu) in the human brain, where the neurotransmitter is present at millimolar concentration [2] . Glutamate demonstrates fast amine exchange rates, giving rise to a strong CEST effect at a resonance offset of +3 ppm from the water frequency (GluCEST), which is dependent on glutamate concentration and pH.
The bacterial enzyme carboxypeptidase G2 (CPG2; EC 3.4.17.11) is a zinc-dependent enzyme which mediates the release of the C-terminal glutamate residue from a wide range
Correspondence to: Yann Jamin; e-mail: yann.jamin@icr.ac.uk of N-acylating moieties, including peptidyl, aminoacyl, benzoyl, benzyloxycarbonyl, folyl, and pteroyl groups (Fig. 1 ). This unique ability of CPG2 has been exploited to activate carboxyl, phenol, or aniline mustard prodrugs, in which the DNA alkylating chain has been synthetically deactivated through N-substitution of L-glutamate [3] . CPG2 underpins the genedirected enzyme prodrug therapy (GDEPT) strategy due to enter Phase I clinical evaluation at the Royal Marsden Hospital (UK) in 2013 [4] . In GDEPT, the gene encoding the prodrugactivating enzyme is targeted selectively to the tumor prior to administration of the prodrug, resulting in the activation of the cytotoxic drug specifically in the tumor. The success of CPG2-based GDEPT relies on the careful optimization of the timing of injection of the prodrug following expression of the transgene and the generation of sufficient concentrations of CPG2 in the tumor.
Non-invasive imaging strategies to monitor the prodrugactivating enzyme activity and its bio-distribution would thus be invaluable in guiding the successful translation of this promising therapeutic approach to the clinic [5] . We have previously developed the imaging reporter, 3,5-difluorobenzoyl-L-glutamate (3,5-DFBGlu) and demonstrated that it can be used to monitor CPG2 activity in vivo using 19 F magnetic resonance spectroscopic imaging (MRSI), by exploiting the 1.4 ppm 19 F chemical shift change upon CPG2-mediated cleavage of 3,5-DFBGlu into 3,5-difluorobenzoic acid (3,5-DFBA) [6] .
In this study, we have exploited the differential exchange rates of amine and amide functional groups [2] , to dynamically monitor CPG2 activity through the "activation" of the concentration-dependent GluCEST signal induced by the CPG2-mediated release of glutamate.
Materials and Methods
All studies were performed at 500 MHz on an 11.7 T Bruker Avance (Bruker Instruments) vertical bore magnet equipped with a 5-mm BBO probe. Magnetic field homogeneity was optimized on solutions in which 10 % D 2 O was added to provide a lock signal. Experiments were subsequently performed unlocked without D 2 O.
CEST-NMR
Glutamic acid (monosodium salt) was obtained from Sigma Aldrich. The in vivo reporter molecule of CPG2 activity, 3,5-difluorobenzoyl-L-glutamate (3,5-DFBGlu) was custom-synthesized as previously described [6] . Z spectra of solutions of 10 mM 3,5-DFBGlu, and the products of its CPG2-mediated cleavage, 3,5-DFBA and glutamate, were acquired at 37°C in phosphate-buffered saline (PBS, 1×) at pH 5,6,7, and 8, using a series of spectra (16 averages, TR=14 s) with the saturation frequency at different offset frequency incremented by 0.2 ppm from −5 to 5 ppm from the water resonance. The frequency selective saturation was achieved using continuous wave presaturation with 3 s duration and γB 1 /2π∼155 Hz [2] . Spectra were apodized with a 3-Hz exponential line broadening. Peak areas were measured using TopSpin3.0 (Bruker), and z spectra and magnetization transfer ratio (MTR) asymmetry plot were generated in Excel (Microsoft).
Detection of CPG2 Activity in Purified Solution of CPG2
Purified CPG2 (10 mU; EC 3.4.17.11, Sigma Aldrich, 1 U cleaves ∼2 μmol 3,5-DFBGlu.min −1 [6] ) or vehicle solution was added to a 5-mM solution of 3,5-DFBGlu (in 100 mM phosphate buffer containing 260 μM ZnCl 2 , at pH 7 and maintained at 37°C). A solution containing 10 mU of purified CPG2 alone was also interrogated. 1 H MRS spectra (16 averages, TR=14 s) were acquired 2 h later (to ensure total conversion of 3,5-DFBGlu into glutamate) with either no saturation, or selective saturation at −3 ppm or +3 ppm, using continuous wave presaturation with 3 s duration and γB 1 /2π∼155 Hz. Each spectrum was apodized with a 3-Hz exponential line broadening function. The GluCEST signal was calculated as MTR assym =(M −3ppm −M +3ppm )/M 0 , where M −3ppm and M +3ppm represent the bulk water signals acquired with selective RF saturation at ±3 ppm resonance offset from the water frequency.
Dynamic Detection of CPG2 Activity in Cell Extracts
The generation of β-galactosidase-(β-gal, control) and stCPG2(Q)3-expressing colon carcinoma WiDr stable cell lines used in this study has been described previously [7] . The cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10 % fetal bovine serum (Gibco) at 37°C in a 5 % CO 2 atmosphere. The dense cell monolayers were then extracted as described previously [8] . Briefly, cells were first washed twice with PBS, followed by 5 mL of extraction buffer (250 mM TrisHCl, 10 % (v/v) glycerol, 1 % (v/v) Triton X-100, pH 7) added to the flask. Cells were lysed for 5 min at room temperature. Cell extracts were then spun down in a microfuge (18,000×g) to remove cell debris.
To confirm that CEST MR could detect CPG2 activity via its sensitivity to the CPG2-induced release of glutamate, we purposely used a very low concentration of CPG2-expressing WiDr cell extracts, and interrogated the dynamic changes in the MTR over time due to the slow increase in glutamate concentration. The experiment was also performed in extracts of β-gal-expressing WiDr cells, which provided a control with similar amount of macromolecules. In order to increase the sensitivity of CEST to adapt to the slow CPG2-mediated changes in glutamate concentration, the frequency selective saturation was achieved using continuous wave presaturation with 5 s duration and γB 1 /2π∼ 280Hz. Fifty microliters of extracts was added to 500 μl of a 12-mM solution of 3,5-DFBGlu in 100 mM phosphate buffer, containing 260 μM ZnCl 2 , at pH 7 and maintained at 37°C. The mixed sample was subsequently positioned in the spectrometer and maintained at 37°C. Acquisition of a series of four spectra (four averages, TR=17 s) was thus initiated with either no saturation, or selective saturation at +3 ppm, +2 ppm, or +1 ppm. This sequence was repeated over a period of ∼4 h. As both 3,5-DFBGlu and cell extracts were present in the solution when the first spectrum (reference) was acquired (∼5 min after mixing), contributions of MT effect to the signal caused by the bound pool of water from rigid macromolecules, or intermolecular-mediated NOE effects in the CPG2-or β-gal-expressing cell extracts, although present, will not change over the time of the experiment. Hence, we measured the change of MTR over time rather than the MTR asymmetry (Note that this may not be the case in vivo where full MTR asymmetry should be considered to account for MT and NOE effects as well as other factors including B 0 and B 1 inhomogeneities). Each spectrum was apodised with a 3-Hz exponential line broadening function. Peak areas were calculated using TopSpin3.0 (Bruker) and fitted as MTR=(M 0 −M sat (t))/M 0 in Excel. Glutamate concentration was monitored over time using the CPG2-induced increase in the 1 H resonance of Glu (3.34 ppm, 2H, t, -CH 2 CO 2 ). Spectra (no saturation, or selective saturation at +3 ppm, +2 ppm, or +1 ppm) were added to reach a sufficient signal-to-noise ratio to calculate the peak area of the 3.34 ppm resonance, resulting in a time resolution of ∼10 min. Peak areas were normalized to the final concentration of glutamate (10 mM).
Results Fig. 2 shows z spectra and the magnetization transfer ratio asymmetry (MTR assym ) of the water 1 H NMR signal as a function of saturation offset frequency for 10-mM solutions of the imaging reporter probe 3,5-DFBGlu, and the products of its CPG2-mediated cleavage, 3,5-DFBA and glutamate, at varying pH representative of the physiological range associated with tumors (pH 5-8). Glutamate showed a sharp CEST peak in the z spectrum at +3 ppm offset from the water resonance at lower pH as previously demonstrated [2] , whilst 3,5-DFBA, and most importantly, 3,5-DFBGlu, did not exhibit any detectable CEST effect over this range of pH.
The ability of CEST MR to detect CPG2 activity was subsequently evaluated using a purified solution of CPG2. A ∼3 % GluCEST signal (+3 ppm) was detected 2 h after the addition of 10 mU purified CPG2 to a solution of 5 mM 3,5-DFBGlu (Fig. 3) . No GluCEST signal was detected in enzyme buffer solution of either CPG2 or 3,5-DFBGlu alone.
The ability of CEST MR to detect CPG2 activity through its sensitivity to CPG2-induced increase in glutamate concentration was confirmed in extracts of stCPG2(Q)3 WiDr colon carcinoma cells, genetically engineered to express CPG2, and control WiDr cells, genetically engineered to express β-galactosidase (LacZ WiDr). The addition of 3,5-DFBGlu to the extracts of CPG2-expressing WiDr cells caused a time-dependent increase of the CEST effect at +3 ppm (Fig. 4a) , which was concomitant with the increase in glutamate concentration (Fig. 4b, c) . No change in the CEST effect was observed following addition of 3,5-DFBGlu to the non-CPG2 expressing LacZ WiDr control cell extracts. CPG2 activity was also detected by the change in CEST signal at +2 ppm with improved sensitivity, corroborating the z spectrum of 3,5-DFBGlu and glutamate at pH 7 (Fig. 2) . On the contrary, large fluctuations in the CEST signal at +1 ppm attributed to the proximity of the bulk water peak and phase instability due to the high power pulse, rendered the dynamic monitoring of CPG2 activity difficult (data not shown).
Discussion and Conclusions
This study demonstrates the potential of CEST-MRI to monitor CPG2 activity via its sensitivity to the CPG2-mediated release of glutamate, resulting in the "activation" of GluCEST contrast (+3 ppm). We have previously demonstrated the utility of 19 F MRS, in combination with the imaging reporter 3,5-DFBGlu, to monitor CPG2 activity in vivo using human tumor xenografts derived from CPG2-expressing WiDr cells, exploiting the 1.4-ppm 19 F MRS chemical shift change upon CPG2-mediated cleavage of 3,5-DFBGlu [6] . Although the 19 F MRS approach provides invaluable information on the level of CPG2 activity in the tumor, the inherent lack of sensitivity of 19 F MRS precluded the assessment of the heterogeneous distribution of enzyme activity within the tumor, an important prognostic factor for successful therapy. We also investigated if the increased signal provided by hyperpolarized 13 C MRS could be utilized to detect and potentially provide CPG2 activity maps. While CPG2 activity was successfully detected in vitro, we concluded that the relatively short T 1 of the 13 C within 3,5-DFBGlu would only afford a short 13 C signal enhancement time window, making the translation of the approach in vivo challenging [9] .
GluCEST MRI is an attractive method for metabolic imaging of glutamate since it utilizes the bulk signal from water protons, providing a signal enhancement of ∼700-fold, enabling the indirect detection of glutamate concentration at higher temporal and spatial resolution compared to its conventional direct detection by 1 H MRS [2] . The release of glutamate from the amido, carbonyl, or ureido bonds is the hallmark of CPG2 activity. As a result, the approach could be applied to substrates of CPG2, including natural substrates such as folic acid, methotrexate (MTX; CPG2 is approved for use in MTX overdose), the noninvasive imaging reporter 3,5-DFBGlu, and, most interestingly, to the arsenal of prodrugs designed for GDEPT using CPG2. The change in glutamate concentration measured with GluCEST MRI could provide a noninvasive biomarker of CPG2 activity, in addition to acting as a surrogate for prodrug activation and the concentration of activated drug in the tumor. The information provided on the active drug is of particular interest in the clinical setting, as the extremely short half-life of the active drug precludes the direct measure of its intra-tumoral concentration [3] .
The activity of cytosine deaminase (CD), another prodrug activating enzyme utilized in GDEPT, has been previously monitored using CEST MRI in vitro [10] . CD mediates the conversion of the prodrug 5-fluorocytosine or cytosine into the conventional chemotherapy agent 5-fluorouracil and uracil, respectively, through the removal of a CEST active amine group. CD activity thus leads to a reduction of the CEST signal (negative contrast). CPG2 activity offers more favorable characteristics than CD towards CEST MRI, since it is sensitive to CPG2-mediated glutamate production (positive contrast).
Glutamate metabolism and diffusion out of the extracellular space may potentially cause limitations for the translation of the approach in vivo. The success of CPG2 detection with CEST MRI will thus depend on the intra-tumoral CPG2 activity levels, CEST sensitivity, and careful optimization of the CEST MRI acquisition time. In the forthcoming clinical trial, CPG2 will be targeted to the tumor using a replication-competent adenoviral vector. These vectors drive the infected cell to express CPG2 whilst replicating. The vector is designed to target and infect tumor cells following intravenous delivery, and to release both CPG2 and CPG2-armed virus into the extracellular space.
Preclinically, the use of such vectors results in CPG2 concentrations of up to 100 units/g of tumor [11] . Since CPG2 has favorable kinetics, this excess of enzyme is able to cleave the prodrug and release glutamate in the tumor within minutes of prodrug administration, as we demonstrated using 19 F MRSI [6] . Elevated levels of glutamate, typically between 5 and 10 mM, have been detected in a range of human solid tumors [12] . This, coupled with the slightly acidic pH associated with tumors, means that the endogenous pool of glutamate (both extra and intracellular) should provide a significant baseline GluCEST signal. This would provide the opportunity to assess GluCEST reproducibility in each animal/patient through the acquisition of two baseline GluCEST measurements, enhancing the accuracy of the detection of the subsequent changes in GluCEST signal induced by the CPG2-mediated millimolar increase in glutamate concentration, following intravenous injection of the prodrug or 3,5-DFBGlu [6] .
The combined excellent temporal resolution of GluCEST MRI protocols as demonstrated by Cai and colleagues [2] , and the high levels of CPG2 intra-tumoral activity, should provide a sufficient temporal imaging window during which the contribution of glutamate metabolism and diffusion into the extracellular space is minimized.
Conclusion
This study thus encourages the in vivo assessment of GluCEST-MRI for imaging CPG2 activity. 
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